BDTX and Brain Metastases: Why CNS Activity Could Matter in 2026
Source ↗
👁 2
💬 0
BDTX spotlights silevertinib's 86% CNS response in NSCLC, with 2026 durability data and a glioblastoma push shaping its brain-metastasis strategy.
Comments (0)